<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6878F160-3C35-4AC6-8D56-FBD6D6FB37B4"><gtr:id>6878F160-3C35-4AC6-8D56-FBD6D6FB37B4</gtr:id><gtr:name>Amgen Inc</gtr:name><gtr:address><gtr:line1>One Amgen Center Drive</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/102F2A51-71E4-4ECA-A245-9B9C4858D7E4"><gtr:id>102F2A51-71E4-4ECA-A245-9B9C4858D7E4</gtr:id><gtr:name>MRC Harwell</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>The Roslin Institute</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6878F160-3C35-4AC6-8D56-FBD6D6FB37B4"><gtr:id>6878F160-3C35-4AC6-8D56-FBD6D6FB37B4</gtr:id><gtr:name>Amgen Inc</gtr:name><gtr:address><gtr:line1>One Amgen Center Drive</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/102F2A51-71E4-4ECA-A245-9B9C4858D7E4"><gtr:id>102F2A51-71E4-4ECA-A245-9B9C4858D7E4</gtr:id><gtr:name>MRC Harwell</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/DF50DBA1-B0D1-49BC-BBAB-64BB83E2CE00"><gtr:id>DF50DBA1-B0D1-49BC-BBAB-64BB83E2CE00</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:otherNames>Bruce</gtr:otherNames><gtr:surname>Whitelaw</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2B4266F0-491C-4E62-8ACD-5B9F118ABAB0"><gtr:id>2B4266F0-491C-4E62-8ACD-5B9F118ABAB0</gtr:id><gtr:firstName>Colin</gtr:firstName><gtr:surname>Farquharson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/28846F08-04C0-464B-A734-9F18E8D39C52"><gtr:id>28846F08-04C0-464B-A734-9F18E8D39C52</gtr:id><gtr:firstName>Thomas</gtr:firstName><gtr:otherNames>Grant</gtr:otherNames><gtr:surname>Burdon</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/04500FFE-1F94-4408-9BD3-DF03F442C094"><gtr:id>04500FFE-1F94-4408-9BD3-DF03F442C094</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>Arthur</gtr:otherNames><gtr:surname>Hume</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0901193"><gtr:id>BA67F8FC-48EA-4B9C-96E3-84F83FA4FD84</gtr:id><gtr:title>CSF1 and the control of postnatal growth and organ development in the rat</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0901193</gtr:grantReference><gtr:abstractText>During pregnancy, many major organs of the body gain the many functions that will be necessary for life outside of the womb. Effects on growth at these early stages of life can have profound consequences for adult health. Most of the events that determine final body mass and function are controlled by protein found circulating in blood. This factor is called Insulin Growth Factor-1 (IGF1). Traditional knowledge indicates that this factor is made in the liver in response to growth hormone (GH) signals. We propose that this is not the entire picture and another factor ? Cytokine Stimulating Factor 1 (CSF1) - produced by the immune cells called macrophages contribute to the control the GH/IGF-1 system and thus contribute to the control of postnatal growth. We base this hypothesis on our data indicating that animals which lack CSF1 function have a range of developmental and growth abnormalities in common to animals deficient in GH/IGF-1. Although our preliminary data is compelling, the challenge remains to understand how these various factors interact to control growth. With this knowledge we will be better able to evaluate strategies to overcome growth impairment. To address these goals we aim to exploit new transgenic technologies in the rat. Specifically we will determine the consequence of reducing CSF1 signalling on growth and beneficial effects of elevating CSF1 levels as a possible treatment of impaired growth.</gtr:abstractText><gtr:technicalSummary>In the third trimester of embryonic development, many major organs mature and develop functions that will be necessary for life outside of the womb. Most of the events that determine final body mass, as well as organ maturation, are controlled by Insulin Growth Factor-1 (IGF1). It is widely accepted that IGF1 is a circulating regulator produced by the liver in response to growth hormone (GH). We propose that through CSF1 activity macrophages contribute to the control the GH/IGF-1 system and thus contribute to the control of postnatal growth. Rats and mice that lack CSF1 signalling are macrophage deficient with many developmental abnormalities in common to animals deficient in GH/IGF-1 signalling. To confirm this view administering CSF-1 to new born mice had increased macrophage numbers and an overall increase of 30-40% in total body weight with corresponding enhanced maturity of organ function. Although this preliminary data is compelling, the challenge remains to understand the mechanistic regulation of the CSF-IGF-GH axis to underpin translation of this knowledge into application. To address these goals we aim to exploit new transgenic technologies in the rat to investigate the consequence of reducing CSF1 signalling on growth and elevating CSF1 levels as treatment of impaired growth. To do this we will exploit the lead position we have at The Roslin Institute in rat ES lines. Using this technology we propose to generate and evaluate both CSF1R-knockout and CSF1R-reporter rats to directly address these goals. This will provide a large animal model to evaluate CSF1-replacement strategies. There is a clear biological focus to this target in providing a basis for future therapeutic applications of CSF1 in humans, but it is also attractive as proof of concept for gene targeting in the rat system.</gtr:technicalSummary><gtr:fund><gtr:end>2014-06-11</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-07-12</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>650243</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Amgen Inc</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Preclinical evaluation of anti-CSF1R</gtr:description><gtr:id>B6A75639-57FC-4401-B53F-3D981CCFCBC9</gtr:id><gtr:impact>Likely IP and commercial application, possible extension to veterinary species</gtr:impact><gtr:outcomeId>qCsGPTwjevc-1</gtr:outcomeId><gtr:partnerContribution>Partners have provided large amounts of antibody</gtr:partnerContribution><gtr:piContribution>We have conducted ongoing research on the efficacy of antibodies against the CSF1 receptor in mouse models.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pfizer Ltd</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:department>Pfizer Animal Health</gtr:department><gtr:description>Development of CSF1 as a therapeutic agent</gtr:description><gtr:id>52BDBCF5-B877-4AC3-A6F1-4EC97F721B9E</gtr:id><gtr:impact>Publications
Patents</gtr:impact><gtr:outcomeId>jcQKkShiuwv-1</gtr:outcomeId><gtr:partnerContribution>They have produced materials for testing, and conducted parallel large-scale testing in animals</gtr:partnerContribution><gtr:piContribution>We have developed novel forms of CSF-1, new bioassays and tested them in mice, rats, chickens and pigs in various disease models</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>MRC Harwell</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Mammalian Genetics Unit</gtr:department><gtr:description>MRC Mouse Network</gtr:description><gtr:id>BA23036D-C493-4926-A66F-01D095A862AF</gtr:id><gtr:impact>Submitted funding application rejected by MRC</gtr:impact><gtr:outcomeId>TfoB84dsFj4-1</gtr:outcomeId><gtr:partnerContribution>Produced joint funding application</gtr:partnerContribution><gtr:piContribution>We participated as a Consortium in Innate Immunity and Macrophage Biology</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A form of recombinant CSF-1 with much greater biological activity in vivo</gtr:description><gtr:id>F289E6A6-60A9-4180-AF5B-0CD2E6226FEA</gtr:id><gtr:impact>We believe it is will have significant clinical applications in tissue repair, based upon preclinical evaluation in mice and pigs</gtr:impact><gtr:outcomeId>hH14285kRBk</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Modified CSF-1</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>355DEC8F-BFC7-4671-82C4-2276808CE13C</gtr:id><gtr:title>Cloning and expression of porcine Colony Stimulating Factor-1 (CSF-1) and Colony Stimulating Factor-1 Receptor (CSF-1R) and analysis of the species specificity of stimulation by CSF-1 and Interleukin 34.</gtr:title><gtr:parentPublicationTitle>Cytokine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f039d09bab7e0936fd21c45aaa27b832"><gtr:id>f039d09bab7e0936fd21c45aaa27b832</gtr:id><gtr:otherNames>Gow DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1043-4666</gtr:issn><gtr:outcomeId>pm_15246_26_22974529</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A961D1C-23B4-40AA-A711-A3C6FFFC4863</gtr:id><gtr:title>Colony-stimulating factor-1 promotes kidney growth and repair via alteration of macrophage responses.</gtr:title><gtr:parentPublicationTitle>The American journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/706792fd758ad8e847bc732b0604a9ee"><gtr:id>706792fd758ad8e847bc732b0604a9ee</gtr:id><gtr:otherNames>Alikhan MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0002-9440</gtr:issn><gtr:outcomeId>pm_15246_26_21762674</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F12A02D-C33A-40C1-803A-C23F4F370A56</gtr:id><gtr:title>Lentiviral vectors containing mouse Csf1r control elements direct macrophage-restricted expression in multiple species of birds and mammals.</gtr:title><gtr:parentPublicationTitle>Molecular therapy. Methods &amp; clinical development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74d5879bbe5b2051862dea3b11956d81"><gtr:id>74d5879bbe5b2051862dea3b11956d81</gtr:id><gtr:otherNames>Pridans C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2329-0501</gtr:issn><gtr:outcomeId>545c8f00969bb1.75921109</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF857238-F1F4-4D5E-84C8-2FD73E7D4F4B</gtr:id><gtr:title>The MacBlue binary transgene (csf1r-gal4VP16/UAS-ECFP) provides a novel marker for visualisation of subsets of monocytes, macrophages and dendritic cells and responsiveness to CSF1 administration.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/740c6af898ac5a0f7fa20fd226968f91"><gtr:id>740c6af898ac5a0f7fa20fd226968f91</gtr:id><gtr:otherNames>Sauter KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_55f94519451c77d4d</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>121B6620-5E9C-4309-8B85-0C50DE6B8A28</gtr:id><gtr:title>The function of the conserved regulatory element within the second intron of the mammalian Csf1r locus.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/740c6af898ac5a0f7fa20fd226968f91"><gtr:id>740c6af898ac5a0f7fa20fd226968f91</gtr:id><gtr:otherNames>Sauter KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_15246_26_23383005</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>07782824-5048-40FF-8A01-3588C2E1C124</gtr:id><gtr:title>Macrophage therapy for murine liver fibrosis recruits host effector cells improving fibrosis, regeneration, and function.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bbb6c2dbdbbbb0453b95e990fc58eae7"><gtr:id>bbb6c2dbdbbbb0453b95e990fc58eae7</gtr:id><gtr:otherNames>Thomas JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>pm_15246_26_21433043</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5762ABD-1671-4EB8-A9E3-4E4536BF8BA4</gtr:id><gtr:title>CSF1R mutations in hereditary diffuse leukoencephalopathy with spheroids are loss of function.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74d5879bbe5b2051862dea3b11956d81"><gtr:id>74d5879bbe5b2051862dea3b11956d81</gtr:id><gtr:otherNames>Pridans C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>pm_15246_26_24145216</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E305011-4050-4823-84D9-7B5299F4ACD5</gtr:id><gtr:title>Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis.</gtr:title><gtr:parentPublicationTitle>Immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bc585bc5d8f6c7b3e50b24df33f1b12d"><gtr:id>bc585bc5d8f6c7b3e50b24df33f1b12d</gtr:id><gtr:otherNames>Yona S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1074-7613</gtr:issn><gtr:outcomeId>pm_15246_26_23273845</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62B20B69-CCB4-473F-9737-C23810C7ADB4</gtr:id><gtr:title>Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/33a19c5b757d89036ac7d90155855752"><gtr:id>33a19c5b757d89036ac7d90155855752</gtr:id><gtr:otherNames>Hume DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_15246_26_22186992</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>277F71E4-9A44-4016-90CF-234A0531BCEB</gtr:id><gtr:title>CX3CR1 reduces Ly6Chigh-monocyte motility within and release from the bone marrow after chemotherapy in mice.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d06c18f9349b6c424e8ec6165042093"><gtr:id>3d06c18f9349b6c424e8ec6165042093</gtr:id><gtr:otherNames>Jacquelin S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_15246_26_23775714</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C3EE850-BF28-44AA-9B5F-80D1F2ED86C0</gtr:id><gtr:title>IL-4 directly signals tissue-resident macrophages to proliferate beyond homeostatic levels controlled by CSF-1.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40e632b492e4640587d6c0586e176f47"><gtr:id>40e632b492e4640587d6c0586e176f47</gtr:id><gtr:otherNames>Jenkins SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>pm_15246_26_24101381</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B0AD8D0F-B3FC-400C-B030-B9662A491C80</gtr:id><gtr:title>Cloning and expression of feline colony stimulating factor receptor (CSF-1R) and analysis of the species specificity of stimulation by colony stimulating factor-1 (CSF-1) and interleukin-34 (IL-34).</gtr:title><gtr:parentPublicationTitle>Cytokine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f039d09bab7e0936fd21c45aaa27b832"><gtr:id>f039d09bab7e0936fd21c45aaa27b832</gtr:id><gtr:otherNames>Gow DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1043-4666</gtr:issn><gtr:outcomeId>545c8f0063b0e1.71136434</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0901193</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>FA7AA693-7EDD-4A7E-8CA3-6B5658FBF717</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Reproductive Health and Childbirth</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>